Suppr超能文献

芬坎法明的强化特性:多巴胺和阿片受体的参与。

Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors.

作者信息

Planeta C da S, Aizenstein M L, DeLucia R

机构信息

Departamento de Principios Ativos Naturais e Toxicologia, Faculdade de Ciências Farmacêuticas, UNESP, Araraquara, Brazil.

出版信息

Pharmacol Biochem Behav. 1995 Jan;50(1):35-40. doi: 10.1016/0091-3057(94)00236-c.

Abstract

Fencamfamine (FCF) is a psychostimulant classified as an indirect dopamine agonist. The conditioning place preference (CPP) paradigm was used to investigate the reinforcing properties of FCF. After initial preferences had been determined, animals were conditioned with FCF (1.75, 3.5, or 7.0 mg/kg; IP). Only at the dose of 3.5 mg/kg FCF produced a significant place preference. Pretreatment with SCH23390 (0.05 mg/kg; SC) or naloxone (1.0 mg/kg; SC) 10 min before FCF (3.5 mg/kg, IP) blocked both FCF-induced hyperactivity and CPP. Pretreatment with metoclopramide (10.0 mg/kg; IP) or pimozide (1.0 mg/kg, IP), respectively, 30 min or 4 h before FCF (3.5 mg/kg; IP), which blocked the FCF-induced locomotor activity, failed to influence place conditioning produced by FCF. In conclusion, the present study suggests that dopamine D1 and opioid receptors are related to FCF reinforcing effect, while dopamine D2 subtype receptor was ineffective in modifying FCF-induced CPP.

摘要

芬坎法明(FCF)是一种被归类为间接多巴胺激动剂的精神兴奋剂。采用条件性位置偏爱(CPP)范式来研究FCF的强化特性。在确定初始偏爱后,对动物给予FCF(1.75、3.5或7.0mg/kg;腹腔注射)进行条件化训练。仅3.5mg/kg剂量的FCF产生了显著的位置偏爱。在给予FCF(3.5mg/kg,腹腔注射)前10分钟,用SCH23390(0.05mg/kg;皮下注射)或纳洛酮(1.0mg/kg;皮下注射)预处理,可阻断FCF诱导的多动和CPP。在给予FCF(3.5mg/kg;腹腔注射)前30分钟或4小时,分别用甲氧氯普胺(10.0mg/kg;腹腔注射)或匹莫齐特(1.0mg/kg,腹腔注射)预处理,它们虽能阻断FCF诱导的运动活动,但未能影响FCF产生的位置条件化。总之,本研究表明多巴胺D1和阿片受体与FCF的强化作用有关,而多巴胺D2亚型受体在改变FCF诱导的CPP方面无效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验